← Back to Search

Other

Abbreviated CT-156 for Schizophrenia

N/A

Waitlist Available

Research Sponsored by Click Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Is an adult at least 18 years of age at the time of informed consent

Meets diagnostic criteria for a primary diagnosis of schizophrenia as defined in the International Classification of Diseases, Eleventh Edition (ICD-11) or Diagnostic Statistical Manual, Fifth Edition (DSM-5) for at least 6 months prior to screening

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 0 to week 4

Awards & highlights

Study Summary

This trial looks at whether a shorter treatment for schizophrenia is safe and works well for people with the condition.

Who is the study for?

Adults over 18 with schizophrenia, fluent in English, living in the US, on stable antipsychotic medication for at least 3 months. They must be able to use a smartphone and an app for study communications. Excluded are those with acute symptoms preventing engagement with the app or on certain therapies like clozapine or multiple antipsychotics.Check my eligibility

What is being tested?

The trial is testing CT-156-C-001's effects and practicality over four weeks in people with schizophrenia. Participants will be divided into two groups to compare outcomes using this new treatment approach alongside their regular medications.See study design

What are the potential side effects?

Since specific side effects of CT-156-C-001 aren't listed, they may include typical reactions to psychiatric treatments such as dizziness, sleep issues, changes in appetite or mood swings. The exact profile will be monitored throughout the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have been diagnosed with schizophrenia for at least 6 months.

Select...

I have been on the same antipsychotic medication for at least 3 months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 0 to week 4

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 0 to week 4

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 0 to week 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Length of time in App

Number of days used

Number of tasks completed

+1 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: CT-156 + UXRExperimental Treatment1 Intervention

Study app investigational treatment for adult patients diagnosed with schizophrenia with up to five in-patient visits with three interviews for UXR (user experience research) arm.

Group II: CT-156Active Control1 Intervention

Study app investigational treatment for adult patients diagnosed with schizophrenia.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CT-156-C-001

2023

N/A

~60

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Boehringer IngelheimIndustry Sponsor

2,505 Previous Clinical Trials

11,340,239 Total Patients Enrolled

14 Trials studying Schizophrenia

5,549 Patients Enrolled for Schizophrenia

Click Therapeutics, Inc.Lead Sponsor

15 Previous Clinical Trials

2,914 Total Patients Enrolled

4 Trials studying Schizophrenia

746 Patients Enrolled for Schizophrenia

Shaheen LakhanStudy DirectorClick Therapeutics

3 Previous Clinical Trials

410 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the cap on participants in this medical research?

"Yes, the information available on clinicaltrials.gov validates that this medical trial is seeking patient recruitment at present. This research was initially posted on September 20th of 2023 and has been modified most recently on November 13th of the same year. 50 participants are needed from a single site in order to complete this study."

Answered by AI

Is enrollment for this experiment still ongoing?

"Affirmative. According to clinicaltrials.gov, this research program is actively searching for volunteers; it was first introduced on September 20th 2023 and subsequently updated November 13th of the same year. The study requires 50 participants from a single medical facility."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

2023. "A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06136936.